Related references
Note: Only part of the references are listed.Epigenetic Alterations in Renal Cell Cancer With TKIs Resistance: From Mechanisms to Clinical Applications
Qinhan Li et al.
FRONTIERS IN GENETICS (2021)
Estrogen receptor β promotes the vasculogenic mimicry (VM) and cell invasion via altering the lncRNA-MALAT1/miR-145-5p/NEDD9 signals in lung cancer
Weiwei Yu et al.
ONCOGENE (2019)
Cancer stem cell (a)symmetry & plasticity: Tumorigenesis and therapy
Masoud Najafi et al.
LIFE SCIENCES (2019)
Emerging roles of lncRNAs in the post-transcriptional regulation in cancer
Rong-Zhang He et al.
GENES & DISEASES (2019)
ERβ-Mediated Alteration of circATP2B1 and miR-204-3p Signaling Promotes Invasion of Clear Cell Renal Cell Carcinoma
Zhenwei Han et al.
CANCER RESEARCH (2018)
ZEB1-mediated vasculogenic mimicry formation associates with epithelial-mesenchymal transition and cancer stem cell phenotypes in prostate cancer
Hua Wang et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2018)
Analysis of the androgen receptor-regulated lncRNA landscape identifies a role for ARLNC1 in prostate cancer progression
Yajia Zhang et al.
NATURE GENETICS (2018)
Estrogen receptor β promotes renal cell carcinoma progression via regulating LncRNA HOTAIR-miR-138/200c/204/217 associated CeRNA network
Jie Ding et al.
ONCOGENE (2018)
TR4 nuclear receptor promotes clear cell renal cell carcinoma (ccRCC) vasculogenic mimicry (VM) formation and metastasis via altering the miR490-3p/vimentin signals
Jian Bai et al.
ONCOGENE (2018)
Cancer Stem Cell Metabolism and Potential Therapeutic Targets
Vusala Snyder et al.
FRONTIERS IN ONCOLOGY (2018)
Targeting newly identified ER beta/TGF-beta 1/SMAD3 signals with the FDA-approved anti-estrogen Faslodex or an ER beta selective antagonist in renal cell carcinoma
Wenbin Song et al.
MOLECULAR ONCOLOGY (2018)
Vasculogenic mimicry formation in EBV-associated epithelial malignancies
Tong Xiang et al.
NATURE COMMUNICATIONS (2018)
Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma
James J. Hsieh et al.
EUROPEAN UROLOGY (2017)
Vasculogenic mimicry signaling revisited: focus on non-vascular VE-cadherin
Daniel Delgado-Bellido et al.
MOLECULAR CANCER (2017)
Current Clinical Practice Guidelines for the Treatment of Renal Cell Carcinoma: A Systematic Review and Critical Evaluation
Aristotle Bamias et al.
ONCOLOGIST (2017)
Renal cell carcinoma
James J. Hsieh et al.
NATURE REVIEWS DISEASE PRIMERS (2017)
Inhibition of Six1 affects tumour invasion and the expression of cancer stem cell markers in pancreatic cancer
Tristan Lerbs et al.
BMC CANCER (2017)
Sequential pathogenesis of metastatic VHL mutant clear cell renal cell carcinoma: putting it together with a translational perspective
N. Shenoy et al.
ANNALS OF ONCOLOGY (2016)
Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
B. Escudier et al.
ANNALS OF ONCOLOGY (2016)
Exosome-Transmitted lncARSR Promotes Sunitinib Resistance in Renal Cancer by Acting as a Competing Endogenous RNA
Le Qu et al.
CANCER CELL (2016)
A Small-Molecule Antagonist of HIF2α Is Efficacious in Preclinical Models of Renal Cell Carcinoma
Eli M. Wallace et al.
CANCER RESEARCH (2016)
The Presence of Vascular Mimicry Predicts High Risk of Clear Cell Renal Cell Carcinoma after Radical Nephrectomy
Lin Zhou et al.
JOURNAL OF UROLOGY (2016)
ITGA6 is directly regulated by hypoxia-inducible factors and enriches for cancer stem cell activity and invasion in metastatic breast cancer models
Danielle L. Peacock Brooks et al.
MOLECULAR CANCER (2016)
Targeting renal cell carcinoma with a HIF-2 antagonist
Wenfang Chen et al.
NATURE (2016)
On-target efficacy of a HIF-2α antagonist in preclinical kidney cancer models
Hyejin Cho et al.
NATURE (2016)
Vasculogenic mimicry in small cell lung cancer
Stuart C. Williamson et al.
NATURE COMMUNICATIONS (2016)
The landscape of long noncoding RNAs in the human transcriptome
Matthew K. Iyer et al.
NATURE GENETICS (2015)
Sunitinib objective response in metastatic renal cell carcinoma: Analysis of 1059 patients treated on clinical trials
A. M. Molina et al.
EUROPEAN JOURNAL OF CANCER (2014)
Tumour vasculogenic mimicry is associated with poor prognosis of human cancer patients: A systemic review and meta-analysis
Zhifei Cao et al.
EUROPEAN JOURNAL OF CANCER (2013)
Clinical Significances and Prognostic Value of Cancer Stem-Like Cells Markers and Vasculogenic Mimicry in Renal Cell Carcinoma
Yanhui Zhang et al.
JOURNAL OF SURGICAL ONCOLOGY (2013)
lncRNA-dependent mechanisms of androgen-receptor-regulated gene activation programs
Liuqing Yang et al.
NATURE (2013)
CD133+ cells with cancer stem cell characteristics associates with vasculogenic mimicry in triple-negative breast cancer
T. J. Liu et al.
ONCOGENE (2013)
Tumor Cell Vasculogenic Mimicry From Controversy to Therapeutic Promise
Richard E. B. Seftor et al.
AMERICAN JOURNAL OF PATHOLOGY (2012)
In Vivo Identification of Tumor-Suppressive PTEN ceRNAs in an Oncogenic BRAF-Induced Mouse Model of Melanoma
Florian A. Karreth et al.
CELL (2011)
A new alternative mechanism in glioblastoma vascularization: tubular vasculogenic mimicry
Soufiane El Hallani et al.
BRAIN (2010)
Sunitinib Acts Primarily on Tumor Endothelium rather than Tumor Cells to Inhibit the Growth of Renal Cell Carcinoma
Dan Huang et al.
CANCER RESEARCH (2010)
Defects of Prostate Development and Reproductive System in the Estrogen Receptor-alpha Null Male Mice
Ming Chen et al.
ENDOCRINOLOGY (2009)
Vasculogenic mimicry: Current status and future prospects
Shiwu Zhang et al.
CANCER LETTERS (2007)
Molecular basis for sunitinib efficacy and future clinical development
Sandrine Faivre et al.
NATURE REVIEWS DRUG DISCOVERY (2007)
Vasculogenic mimicry and tumour-cell plasticity: Lessons from melanoma
MJC Hendrix et al.
NATURE REVIEWS CANCER (2003)
Vasculogenic mimicry and tumor angiogenesis
R Folberg et al.
AMERICAN JOURNAL OF PATHOLOGY (2000)
Share Paper
